- Home
- OTLK vs FAAS Comparison
OTLK vs FAAS Comparison
Compare OTLK & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- FAAS
- Stock Information
- Founded
- OTLK 2010
- FAAS 2021
- Country
- OTLK United States
- FAAS Indonesia
- Employees
- OTLK N/A
- FAAS N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- FAAS
- Sector
- OTLK Health Care
- FAAS
- Exchange
- OTLK Nasdaq
- FAAS NYSE
- Market Cap
- OTLK 48.3M
- FAAS 48.2M
- IPO Year
- OTLK 2016
- FAAS N/A
- Fundamental
- Price
- OTLK $1.71
- FAAS $0.57
- Analyst Decision
- OTLK Strong Buy
- FAAS
- Analyst Count
- OTLK 5
- FAAS 0
- Target Price
- OTLK $9.60
- FAAS N/A
- AVG Volume (30 Days)
- OTLK 823.9K
- FAAS 20.3M
- Earning Date
- OTLK 08-13-2025
- FAAS 01-01-0001
- Dividend Yield
- OTLK N/A
- FAAS N/A
- EPS Growth
- OTLK N/A
- FAAS N/A
- EPS
- OTLK 0.83
- FAAS N/A
- Revenue
- OTLK N/A
- FAAS $57,730,593.00
- Revenue This Year
- OTLK N/A
- FAAS N/A
- Revenue Next Year
- OTLK $379.84
- FAAS N/A
- P/E Ratio
- OTLK $2.06
- FAAS N/A
- Revenue Growth
- OTLK N/A
- FAAS 38.16
- 52 Week Low
- OTLK $0.87
- FAAS $0.16
- 52 Week High
- OTLK $9.25
- FAAS $8.49
- Technical
- Relative Strength Index (RSI)
- OTLK 46.49
- FAAS 48.67
- Support Level
- OTLK $1.65
- FAAS $0.57
- Resistance Level
- OTLK $1.97
- FAAS $0.69
- Average True Range (ATR)
- OTLK 0.12
- FAAS 0.18
- MACD
- OTLK -0.03
- FAAS -0.04
- Stochastic Oscillator
- OTLK 10.94
- FAAS 9.73
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.